The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The firm will use the award to develop silica nanomaterial for use with many sample types, including blood, cultured cells, and pathogens.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
In Science this week: gene flow between ancient chimpanzees and bonobos, and more.
A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.
Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.
In Nature this week: genetic history of HIV in the US, and more.